LSL Pharma Group Inc. LSL.V
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · groupelslpharma.com
LSL Pharma Group develops, manufactures, and commercializes sterile pharmaceutical products, cosmetic products, and natural health products for the Canadian, U.S., and international markets through subsidiaries including Steri-Med Pharma, Laboratoire LSL, Virage Santé, and Dermolab Pharma.
Key ratios
FreeCashFlowOnSale TTM 0.02
FreeCashFlowOnSale 2024 -0.18
FreeCashFlowOnSale 2023 -0.77
FreeCashFlowOnSale 2022 -0.51
NetIncomeMargin TTM 0.1
NetIncomeMargin 2024 0.19
NetIncomeMargin 2023 -0.84
NetIncomeMargin 2022 -0.98
ReturnOnAssets TTM 0.02
ReturnOnAssets 2024 0.01
ReturnOnAssets 2023 -0.09
ReturnOnAssets 2022 -0.15
ReturnOnEquity TTM 0.12
ReturnOnEquity 2024 0.2
ReturnOnEquity 2023 -1.22
ReturnOnEquity 2022 -0.98
TotalRevenueYoYGrowth TTM 0.69
TotalRevenueYoYGrowth 2024 0.77
TotalRevenueYoYGrowth 2023 0.22
TotalRevenueYoYGrowth 2022 -0.06
Recent news
LSL Pharma Group Provides Update on Steri-Med Pharma Manufacturing Operations and Grants Compensation Stock Options
2026-07-06 · Newswire (CNW)
LSL PHARMA GROUP ANNOUNCES VOTING RESULTS OF ITS ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS
2026-06-22 · Yahoo Finance Canada
LSL PHARMA GROUP SECURES NEW STERI-MED COMMERCIAL AGREEMENTS EXPECTED TO GENERATE OVER $4 MILLION IN RECURRING ANNUAL REVENUES AND APPOINTS ALAIN R. DUGAL AS NEW EVP & COO
2026-05-28 · BioSpace
LSL PHARMA GROUP REPORTS RECORD REVENUES AND FIRST QUARTER 2026 RESULTS
2026-05-25 · Newswire Canada